News

Acquisition is 3PL provider's largest one yet

Acquisition grows Antares’ track-and-trace presence

The importance of thinking strategically about the infrastructure and foresight needed to scale up CGTs—not as treatments of last resort, but first choice

Strengthens the CRO's scientific capabilities in cell and gene therapy space

Lab development project features 9,000-square-foot expansion

Combine their expertise in immunology and infectious diseases to speed up development of mAbs for influenza

Between both Covid-19 vaccines, an additional 350 million doses are being sent to Europe this year

Acquires Scientific Commercialization, a medical affairs consulting and analytics business

Authorization should activate distribution of hundreds of millions of doses to countries involved with COVAX effort

Deal will help expand its pharma presence

Becomes a partner in UK consortium focused on enabling new and disruptive manufacturing technologies

UK cell and gene therapy location expected to be cGMP-ready by mid-2022

Will help biomed startups in furthering oncology R&D

There are currently 100,000 doses standing by

Results address concerns surrounding bulk passive pharma packaging

Survey of orphan drug commercial operation leaders gives glimpse into market challenges

As efficiencies increase, company aims to cut time from 110 to about 60 days, according to a published report

Report: After data displayed minimal effectiveness, government pauses vaccine rollout

Last year’s numbers indicate historic lows

$180M collaboration aims to introduce multiple vaccine candidates in 2022

Two-dose COVAXIN currently under EUA in India

Rating for packaging supplier highlights its commitment to sustainable practices and corporate social responsibility

CDMO to take over operations, including equipment and workforce, at site in Couvet, Switzerland

Deal completes Verista's lifecycle support for pharma, which now includes consulting, technology and manufacturing

Agreement provides Acentrus with specialty pharmacy accreditation

Following last week's announcement of supply decrease, company raises projection by 9 million

In Phase III at the moment, mRNA dose will be produced at Bayer's Wuppertal, Germany facility

The latest people news happenings over the past month